News and features

To mark our outstanding success in REF2021, Gege Li spoke to several of our researchers here at the ICR who have pioneered improved use of radiotherapy in the treatment of prostate cancer.

To mark our outstanding success in REF2021, Alison Halliday spoke to several of our researchers here at the ICR who were instrumental in the development of PARP inhibitors, a type of targeted drug that’s been approved for use in breast, ovarian and prostate cancer.

To mark our outstanding success in REF2021, Alison Halliday shares the story of how our researchers revealed the 3D structure of the key cancer protein AKT, catalysing the discovery and development of at least 12 drugs now in clinical trials for a variety of cancers.

The Institute of Cancer Research, London, has rated second in REF 2021 – the Government’s evaluation of university research quality – among all higher education institutions in the UK that submitted at least two units of assessment.

Professor Kristian Helin, Chief Executive and President at The Institute of Cancer Research, London, and Professor Trevor Graham, Director of the ICR’s Centre for Evolution and Cancer, have been awarded prestigious Fellowships for the Academy of Medical Sciences (AMS).

The ICR is saddened to learn of the death of Dr Mike Ormerod, who headed the ICR’s flow cytometry facility in Sutton in the 1980s.

Scientists have found a genetic mutation that results in cancer cells being able to tolerate having an abnormal number of chromosomes – a condition which normally kills cells – allowing them to adapt to their environment and continue to grow.

Pancreatic cancers recycle resources to fuel their survival and growth, opening up the possibility of new treatments aimed at stopping them from doing so, scientists report.

A team of scientists has created a three-dimensional map showing how a small molecule with anticancer properties – called spliceostatin – can promote the killing of cancer cells.

Widely considered a revolutionary treatment, immunotherapy has become a powerful tool against cancer. On the International Day of Immunology, Gege Li looks at the progress we are making in our understanding of the immune landscape of cancer to develop more effective treatments for even more people with cancer.

This DNA Day, we look at how our scientists are seeking to understand how cells respond to damage to DNA – and the tricks cancer uses to stay alive despite suffering genetic damage.

Artificial intelligence (AI) could help guide the post-treatment surveillance of non-small cell lung cancer (NSCLC) patients and improve outcomes as a result, according to new research.